Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 7,154 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36. Following the sale, the executive vice president now owns 45,670 shares in the company, valued at approximately $1,499,802.80. This represents a 13.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Swayze also recently made the following trade(s):

• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48.

Ionis Pharmaceuticals Stock Down 2.6 %

Ionis Pharmaceuticals stock traded down $0.85 during mid-day trading on Friday, reaching $31.43. The stock had a trading volume of 1,371,506 shares, compared to its average volume of 1,525,691. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $31.40 and a fifty-two week high of $52.49. The stock’s 50-day simple moving average is $35.63 and its 200-day simple moving average is $41.17. The firm has a market capitalization of $4.96 billion, a PE ratio of -12.88 and a beta of 0.35.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IONS shares. Piper Sandler decreased their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Wells Fargo & Company decreased their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.65.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after buying an additional 183,814 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Ionis Pharmaceuticals by 8.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock worth $57,807,000 after acquiring an additional 114,914 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Ionis Pharmaceuticals by 1.7% in the 3rd quarter. ARK Investment Management LLC now owns 1,384,269 shares of the company’s stock worth $55,454,000 after acquiring an additional 23,244 shares during the last quarter. Two Sigma Advisers LP lifted its position in Ionis Pharmaceuticals by 3.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company’s stock valued at $53,376,000 after acquiring an additional 45,300 shares in the last quarter. Finally, Groupama Asset Managment boosted its stake in Ionis Pharmaceuticals by 4.1% during the 3rd quarter. Groupama Asset Managment now owns 916,060 shares of the company’s stock valued at $367,000 after purchasing an additional 36,084 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.